Literature DB >> 33777621

Optic Nerve Gliomas.

Edward J Wladis1, Matthew A Adamo2, Lauren Weintraub3.   

Abstract

Objectives  To describe the diagnostic and management features of optic nerve gliomas. Design  Literature review. Results  Optic nerve gliomas are generally benign in the pediatric age group although they are usually malignant and aggressive in adults. As such, the mechanisms by which these lesions are diagnosed, the systemic implications, the goals of intervention, and the nature of therapeutic management all differ between these tumors. Conclusions  This article addresses these lesions and discusses the diagnostic and therapeutic paradigms by which they may be approached. Thieme. All rights reserved.

Entities:  

Keywords:  glioma; malignant optic nerve glioma; optic nerve glioma

Year:  2021        PMID: 33777621      PMCID: PMC7987392          DOI: 10.1055/s-0040-1722634

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  58 in total

1.  Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas.

Authors:  D H Gutmann; J Donahoe; T Brown; C D James; A Perry
Journal:  Neuropathol Appl Neurobiol       Date:  2000-08       Impact factor: 8.090

Review 2.  Malignant optic glioma - the spectrum of disease in a case series.

Authors:  Ghislaine L Traber; Athina Pangalu; Manuela Neumann; Joao Costa; Michael Weller; Ruth Huna-Baron; Klara Landau
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-26       Impact factor: 3.117

3.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.

Authors:  Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Grant T Liu
Journal:  Neuro Oncol       Date:  2012-04-03       Impact factor: 12.300

4.  Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

Authors:  Eric Bouffet; Regina Jakacki; Stewart Goldman; Darren Hargrave; Cynthia Hawkins; Manohar Shroff; Juliette Hukin; Ute Bartels; Nicholas Foreman; Stewart Kellie; Joanne Hilden; Michael Etzl; Beverly Wilson; Derek Stephens; Uri Tabori; Sylvain Baruchel
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.

Authors:  Alvaro Lassaletta; Katrin Scheinemann; Shayna M Zelcer; Juliette Hukin; Beverley A Wilson; Nada Jabado; Anne Sophie Carret; Lucie Lafay-Cousin; Valerie Larouche; Cynthia E Hawkins; Gregory Russell Pond; Ken Poskitt; Daniel Keene; Donna L Johnston; David D Eisenstat; Rahul Krishnatry; Matthew Mistry; Anthony Arnoldo; Vijay Ramaswamy; Annie Huang; Ute Bartels; Uri Tabori; Eric Bouffet
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

6.  Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab.

Authors:  Robert A Avery; Eugene I Hwang; Regina I Jakacki; Roger J Packer
Journal:  JAMA Ophthalmol       Date:  2014-01       Impact factor: 7.389

Review 7.  Chiasmal gliomas: results of irradiation management in 57 patients and review of literature.

Authors:  J P Bataini; S Delanian; D Ponvert
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-08       Impact factor: 7.038

8.  Correlation of optical coherence tomography parameters with clinical and radiological progression in patients with symptomatic optic pathway gliomas.

Authors:  Masoud Aghsaei Fard; Sara Fakhree; Bahram Eshraghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-06-05       Impact factor: 3.117

9.  Temozolomide in children with progressive low-grade glioma.

Authors:  Sridharan Gururangan; Michael J Fisher; Jeffrey C Allen; James E Herndon; Jennifer A Quinn; David A Reardon; James J Vredenburgh; Annick Desjardins; Peter C Phillips; Melody A Watral; Jeanne M Krauser; Allan H Friedman; Henry S Friedman
Journal:  Neuro Oncol       Date:  2007-03-08       Impact factor: 12.300

10.  A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Authors:  Anuradha Banerjee; Regina I Jakacki; Arzu Onar-Thomas; Shengjie Wu; Theodore Nicolaides; Tina Young Poussaint; Jason Fangusaro; Joanna Phillips; Arie Perry; David Turner; Michael Prados; Roger J Packer; Ibrahim Qaddoumi; Sridharan Gururangan; Ian F Pollack; Stewart Goldman; Lawrence A Doyle; Clinton F Stewart; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

View more
  2 in total

1.  A Single-Center Treatment Experience of Gamma Knife Radiosurgery for Optic Pathway Glioma.

Authors:  Youlin Ge; Zhiyuan Zhang; Yanhe Li; Yiguang Lin; Yongqing Zong; Dong Liu
Journal:  Biomed Res Int       Date:  2022-08-09       Impact factor: 3.246

2.  miR-223-3p Regulates NLRP3 to Inhibit Proliferation and Promote Apoptosis of ONG Cells.

Authors:  Lili Nie; Hui Zou; Chi Ma; Xiaoke Wang
Journal:  Comput Math Methods Med       Date:  2022-10-04       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.